Arvinas (ARVN) investor relations material

Key achievements and recent approvals

• Achieved first-ever approval of a PROTAC degrader, Veppanu (vepdegestrant), for ER-positive, HER2-negative advanced breast cancer with ESR1 mutations.

• Announced a licensing deal with Rigel to commercialize Veppanu, with Rigel prioritizing it as a top product.

• Maintains strong downstream royalty terms in the Rigel deal, ensuring value even at lower sales tiers.

Pipeline strategy and prioritization

• Focused on advancing programs where differentiated therapies can be developed, while seeking partners for others.

• Four programs currently in phase I: ARV-102 (LRRK2 degrader), ARV-027 (polyQ AR degrader for SBMA), ARV-393 (BCL6 degrader), and ARV-6723 (HPK1 degrader).

• KRAS G12D program (ARV-806) will only advance beyond phase I if a partner is found.

Upcoming milestones and clinical data

• ARV-102: Additional biomarker data and initiation of phase I-B and II trials in PSP later this year.

• ARV-027: Phase I data in healthy volunteers expected in the first half of next year.

• ARV-393: First phase I data in the second half of this year.

• ARV-6723: Phase I trial to start in Q3 this year.

• KRAS G12D phase I escalation data to be disclosed this year.